Thyrocare Technologies shares jump 13% after Q1 PAT surges 60% YoY

Shares of Thyrocare Technologies surged 13% to hit the day's high of Rs 1,357.85 on the NSE on Thursday following the company's Q1 earnings where it reported a 60% year-on-year jump in its net profit at Rs 38 crore versus Rs 24 crore in the year-ago period. The company's revenue from operations also surged in double-digits, rising by 23% to Rs 193 crore compared to Rs 157 crore in the corresponding quarter of the last financial year.
23%.

The gross margin was reported at Rs 137 crore in the quarter under review versus Rs 111 crore in the year ago period, witnessing a 23% growth.


The normalised EBITDA (before ESOP) stood at Rs 63 crore versus Rs 45 crore, a 42% YoY jump while the normalised EBITDA margin was reported at 33% in Q1FY26 versus 29% in Q1FY25.

The consolidated Gross Margin stood at 71%, with reported EBITDA margin at 30%.

The earnings were announced on Wednesday after market hours.

The company said that its Pathology Business Franchise revenue grew by 20% YoY, while partnership revenue surged by 36% YoY.

Total test volume reached 46.9 million in Q1FY26, reflecting a 15% YoY increase.

The diagnostic company opened new labs in Bhagalpur, Kashmir and Roorkee in the quarter ended June 30, 2025.

Thyrocare Technologies is an automated laboratory chain with presence across India. Thyrocare provides diagnostic services to laboratories and hospitals.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)